** Shares of drugmaker Abeona Therapeutics ABEO.O up 12.7% at $6.03 premarket

** ABEO says the U.S. FDA has approved its gene therapy for a rare skin disorder

** The gene therapy, called Zevaskyn, is approved to treat adult and pediatric patients with recessive dystrophic epidermolysis bullosa

** The current standard-of-care treatment is daily wound care and protective bandaging

** Company says the treatment is expected to be available in Q3 2025

** As of last close, ABEO shares down 4% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))